REGENERON PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $61.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $61.40M, a 75.42% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $24.00M, a 82.82% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$338.30M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $210.60M, a 56.58% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$10.60M, a 109.01% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $117.70M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$241.60M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$39.80M, a 110.31% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $61.40M 10-Q · filed 2026-07-30 | $85.40M 10-Q · filed 2026-07-30 | -$252.90M derived: sum of 3 quarters · filed 2026-07-30 | -$42.30M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $24.00M 10-Q · filed 2026-04-29 | -$314.30M derived: sum of 2 quarters · filed 2026-04-29 | -$103.70M derived: sum of 3 quarters · filed 2026-04-29 | $146.10M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | -$338.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$127.70M derived: sum of 2 quarters · filed 2026-02-04 | $122.10M derived: sum of 3 quarters · filed 2026-07-30 | -$10.60M 10-K · filed 2026-02-04 | ||
| 2025-09-30 | $210.60M 10-Q · filed 2025-10-28 | $460.40M derived: sum of 2 quarters · filed 2026-07-30 | $327.70M 10-Q · filed 2025-10-28 | $387.00M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $249.80M 10-Q · filed 2026-07-30 | $389.50M 10-Q · filed 2026-07-30 | $176.40M derived: sum of 3 quarters · filed 2026-07-30 | $310.90M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $139.70M 10-Q · filed 2026-04-29 | -$73.40M derived: sum of 2 quarters · filed 2026-04-29 | $61.10M derived: sum of 3 quarters · filed 2026-04-29 | $453.60M derived: sum of 4 quarters · filed 2026-04-29 | ||
| 2024-12-31 | -$213.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$78.60M derived: sum of 2 quarters · filed 2026-02-04 | $313.90M derived: sum of 3 quarters · filed 2026-02-04 | $117.70M 10-K · filed 2026-02-04 | ||
| 2024-09-30 | $134.50M 10-Q · filed 2025-10-28 | $527.00M derived: sum of 2 quarters · filed 2025-10-28 | $330.80M 10-Q · filed 2025-10-28 | $385.10M derived: sum of 4 quarters · filed 2026-02-04 | ||
| 2024-06-30 | $392.50M 10-Q · filed 2025-08-01 | $196.30M 10-Q · filed 2025-08-01 | $250.60M derived: sum of 3 quarters · filed 2026-02-04 | $150.30M derived: sum of 4 quarters · filed 2026-02-04 | ||
| 2024-03-31 | -$196.20M 10-Q · filed 2025-04-29 | -$141.90M derived: sum of 2 quarters · filed 2026-02-04 | -$242.20M derived: sum of 3 quarters · filed 2026-02-04 | -$273.10M derived: sum of 4 quarters · filed 2026-02-04 | ||
| 2023-12-31 | $54.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$46.00M derived: sum of 2 quarters · filed 2026-02-04 | -$76.90M derived: sum of 3 quarters · filed 2026-02-04 | -$241.60M 10-K · filed 2026-02-04 | -$237.80M 10-K · filed 2024-02-05 | |
| 2023-09-30 | -$100.30M 10-Q · filed 2024-10-31 | -$131.20M derived: sum of 2 quarters · filed 2024-10-31 | -$295.90M 10-Q · filed 2024-10-31 | -$215.10M derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2023-06-30 | -$30.90M 10-Q · filed 2024-08-01 | -$195.60M 10-Q · filed 2024-08-01 | -$114.80M derived: sum of 3 quarters · filed 2025-02-05 | $139.50M derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2023-03-31 | -$164.70M 10-Q · filed 2024-05-02 | -$83.90M derived: sum of 2 quarters · filed 2025-02-05 | $170.40M derived: sum of 3 quarters · filed 2025-02-05 | $6.70M derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2022-12-31 | $80.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $335.10M derived: sum of 2 quarters · filed 2025-02-05 | $171.40M derived: sum of 3 quarters · filed 2025-02-05 | -$39.80M 10-K · filed 2025-02-05 | ||
| 2022-09-30 | $254.30M 10-Q · filed 2023-11-02 | $90.60M derived: sum of 2 quarters · filed 2023-11-02 | -$120.60M 10-Q · filed 2023-11-02 | -$258.30M derived: sum of 4 quarters · filed 2024-02-05 | ||
| 2022-06-30 | -$163.70M 10-Q · filed 2023-08-03 | -$374.90M 10-Q · filed 2023-08-03 | -$512.60M derived: sum of 3 quarters · filed 2024-02-05 | -$541.70M derived: sum of 4 quarters · filed 2024-02-05 | ||
| 2022-03-31 | -$211.20M 10-Q · filed 2023-05-04 | -$348.90M derived: sum of 2 quarters · filed 2024-02-05 | -$378.00M derived: sum of 3 quarters · filed 2024-02-05 | $31.00M derived: sum of 4 quarters · filed 2024-02-05 | ||
| 2021-12-31 | -$137.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | -$166.80M derived: sum of 2 quarters · filed 2024-02-05 | $242.20M derived: sum of 3 quarters · filed 2024-02-05 | $386.10M 10-K · filed 2024-02-05 | ||
| 2021-09-30 | -$29.10M 10-Q · filed 2022-11-03 | $379.90M derived: sum of 2 quarters · filed 2022-11-03 | $523.80M 10-Q · filed 2022-11-03 | $586.00M derived: sum of 4 quarters · filed 2023-02-06 | ||
| 2021-06-30 | $409.00M 10-Q · filed 2022-08-03 | $552.90M 10-Q · filed 2022-08-03 | $615.10M derived: sum of 3 quarters · filed 2023-02-06 | $577.60M derived: sum of 4 quarters · filed 2023-02-06 | ||
| 2021-03-31 | $143.90M 10-Q · filed 2022-05-04 | $206.10M derived: sum of 2 quarters · filed 2023-02-06 | $168.60M derived: sum of 3 quarters · filed 2023-02-06 | $396.70M derived: sum of 4 quarters · filed 2023-02-06 | ||
| 2020-12-31 | $62.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $24.70M derived: sum of 2 quarters · filed 2023-02-06 | $252.80M derived: sum of 3 quarters · filed 2023-02-06 | $196.00M 10-K · filed 2023-02-06 | ||
| 2020-09-30 | -$37.50M 10-Q · filed 2021-11-04 | $190.60M derived: sum of 2 quarters · filed 2021-11-04 | $133.80M 10-Q · filed 2021-11-04 | $310.50M derived: sum of 4 quarters · filed 2022-02-07 | ||
| 2020-06-30 | $228.10M 10-Q · filed 2021-08-05 | $171.30M 10-Q · filed 2021-08-05 | $348.00M derived: sum of 3 quarters · filed 2022-02-07 | $363.70M derived: sum of 4 quarters · filed 2022-02-07 | ||
| 2020-03-31 | -$56.80M 10-Q · filed 2021-05-06 | $119.90M derived: sum of 2 quarters · filed 2022-02-07 | $135.60M derived: sum of 3 quarters · filed 2022-02-07 | $18.70M derived: sum of 4 quarters · filed 2022-02-07 | ||
| 2019-12-31 | $176.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $192.40M derived: sum of 2 quarters · filed 2022-02-07 | $75.50M derived: sum of 3 quarters · filed 2022-02-07 | $118.30M 10-K · filed 2022-02-07 | ||
| 2019-09-30 | $15.70M 10-Q · filed 2020-11-05 | -$101.20M derived: sum of 2 quarters · filed 2020-11-05 | -$58.40M 10-Q · filed 2020-11-05 | -$121.30M derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-06-30 | -$116.90M 10-Q · filed 2020-08-05 | -$74.10M 10-Q · filed 2020-08-05 | -$137.00M derived: sum of 3 quarters · filed 2021-02-08 | -$141.90M derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-03-31 | $42.80M 10-Q · filed 2020-05-05 | -$20.10M derived: sum of 2 quarters · filed 2021-02-08 | -$25.00M derived: sum of 3 quarters · filed 2021-02-08 | -$8.50M derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2018-12-31 | -$62.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | -$67.80M derived: sum of 2 quarters · filed 2021-02-08 | -$51.30M derived: sum of 3 quarters · filed 2021-02-08 | -$41.90M 10-K · filed 2021-02-08 | ||
| 2018-09-30 | -$4.90M 10-Q · filed 2019-11-05 | $4.90M 10-Q · filed 2018-11-06 | $11.60M derived: sum of 2 quarters · filed 2019-11-05 | $21.00M 10-Q · filed 2019-11-05 | -$3.20M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-06-30 | $16.50M 10-Q · filed 2019-08-06 | $25.90M 10-Q · filed 2019-08-06 | $1.70M derived: sum of 3 quarters · filed 2019-08-06 | $29.40M derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $9.40M 10-Q · filed 2019-05-07 | -$14.80M derived: sum of 2 quarters · filed 2019-05-07 | $12.90M derived: sum of 3 quarters · filed 2019-05-07 | $18.70M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | -$24.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $3.50M derived: sum of 2 quarters · filed 2019-02-07 | $9.30M derived: sum of 3 quarters · filed 2019-02-07 | $14.70M 10-K · filed 2019-02-07 | ||
| 2017-09-30 | $27.70M 10-Q · filed 2018-11-06 | $33.50M derived: sum of 2 quarters · filed 2018-11-06 | $38.90M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $5.80M 10-Q · filed 2018-08-02 | $11.20M 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | -$22.60M 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |